

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

✓
Please cancel claims 39, 52 and 59 without prejudice to or disclaimer of the subject matter therein.

✓
Please substitute the following claims 1, 6, 27, 37, 38, 46, 75 and 81 for pending claims 1, 6, 27, 37, 38, 46, 75 and 81:


C¹
1. (Twice amended) A method of treating a disorder responsive to the induction of apoptosis in a mammal suffering therefrom, wherein said disorder is selected from the group consisting of:

- (a) an autoimmune disease;
- (b) inflammation; and

(c) a skin disease;

comprising administering to said mammal an effective amount of a compound of

Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

X is O;

Y is CN;

Z is NR_8R_9 , wherein R_8 and R_9 are independently H or C_{1-4} alkyl;


R_5 is hydrogen or C_{1-10} alkyl;

A is optionally substituted C_{6-14} aryl; and

B is an optionally substituted indolo ring.

6. (Twice amended) The method of claim 1, wherein said compound has the

Formula II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

(a) R_1 - R_4 are independently hydrogen, halo, haloalkyl, aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C_{1-10} alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; provided that R_1 and R_2 , or R_2 and R_3 , or R_3 and R_4 , taken together with the atoms to which they are attached form a pyrrolo group, wherein said group is optionally substituted;

(b) the aryl portion of said arylalkyl, the aryl portion of said arylalkenyl and the aryl portion of said arylalkynyl are each independently C_{6-14} aryl;

(c) said carbocyclic is C_{3-8} cycloalkyl or C_{3-8} cycloalkenyl;


(d) said heteroaryl, the heteroaryl portion of said heteroarylalkyl, the heteroaryl portion of said heteroarylkenyl and the heteroaryl portion of said heteroarylalkynyl are each independently selected from the group consisting of thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranal, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiyl, 2*H*-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indoliziny, isoindolyl, 3*H*-indolyl, indolyl, indazolyl, purinyl, 4*H*-quinoliziny, isoquinolyl, quinolyl, phthalziny, naphthyridinyl, quinozaliny, cinnoliny, pteridinyl, carbazolyl, β -carboliny, phenanthridinyl, acrindiny, perimidiny, phenanthroliny, phenazinyl, isothiazolyl, phenothiaziny, isoxazolyl, furazany, phenoxazinyl, 1,4-dihydroquinoxaline-2,3-dione, 7-aminoisocoumarin,

C2
Cont.

pyrido[1,2-a]pyrimidin-4-one, 1,2-benzisoxazol-3-yl, benzimidazolyl, 2-oxindolyl
2-oxobenzimidazolyl and the N-oxides thereof; and

(e) said heterocyclic and the heterocyclic portion of said heterocycloalkyl are each independently selected from the group consisting of tetrahydrofuranyl, pyranlyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazoliny, indoliny, isoindoliny, quinuclidiny, morpholiny, isochromanyl, chromanyl, pyrazolidiny, pyrazoliny, tetronoyl and tetramoyl.

27. (Once amended) A method of treating a disorder responsive to the induction of apoptosis in a mammal suffering therefrom, wherein said disorder is cancer, comprising administering to said mammal an effective amount of a compound of Formula I:



(I)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

X is O;

Y is CN;

Z is NR₈R₉, wherein R₈ and R₉ are independently H or C₁₋₄alkyl;

R₅ is hydrogen or C₁₋₁₀ alkyl;

A is optionally substituted C₆₋₁₄ aryl; and

C³
cont.

B is an optionally substituted indolo ring.


37. (Once amended) The method of claim 36, wherein said autoimmune disease is rheumatoid arthritis.

C⁴

38. (Once amended) The method of claim 1, wherein said disorder is inflammation.

46. (Twice amended) The pharmaceutical composition of claim 41, comprising a pharmaceutically acceptable excipient or carrier and a compound of Formula II:

C⁵



(II)

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

(a) R₁-R₄ are independently hydrogen, halo, haloalkyl, aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy,

carbonylamido or alkylthiol; provided that R₁ and R₂, or R₂ and R₃, or R₃ and R₄, taken together with the atoms to which they are attached form a pyrrolo group, wherein said group is optionally substituted;

(b) the aryl portion of said arylalkyl, the aryl portion of said arylalkenyl and the aryl portion of said arylalkynyl are each independently C₆₋₁₄ aryl;

(c) said carbocyclic is C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl;


(d) said heteroaryl, the heteroaryl portion of said heteroarylalkyl, the heteroaryl portion of said heteroarylkenyl and the heteroaryl portion of said heteroarylalkynyl are each independently selected from the group consisting of thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiynyl, 2*H*-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizynyl, isoindolyl, 3*H*-indolyl, indolyl, indazolyl, purinyl, 4*H*-quinolizynyl, isoquinolyl, quinolyl, phthalzinyll, naphthyridinyl, quinozalinyll, cinnolinyll, pteridinyl, carbazolyl, β -carbolinyll, phenanthridinyl, acrindinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, 1,4-dihydroquinoxaline-2,3-dione, 7-aminoisocoumarin, pyrido[1,2-a]pyrimidin-4-one, 1,2-benzisoxazol-3-yl, benzimidazolyl, 2-oxindolyl 2-oxobenzimidazolyl and the N-oxides thereof; and

(e) said heterocyclic and the heterocyclic portion of said heterocycloalkyl are each independently selected from the group consisting of tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyll, indolinyll,

C 5
cont.

C5
cont.
isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl
pyrazolinyl, tetronoyl and tetramoyl.

75. (Twice amended) A compound of Formula I:



C6
or a pharmaceutically acceptable salt or prodrug thereof, wherein:

B is optionally substituted indolo;

X is O;

Y is CN;

Z is NR_8R_9 , wherein R_8 and R_9 are independently H or C_{1-4} alkyl;

R_5 is hydrogen or C_{1-10} alkyl; and

A is optionally substituted C_{6-14} aryl.

C7
81. (Once amended) The compound of claim 75, wherein said aryl is selected
from the group consisting of phenyl, naphthyl, penanthrenyl, anthracenyl, indenyl,
azulenyl, biphenyl, biphenylenyl and fluorenyl.

✓
Please add the following new claims:

82. (New) The method of claim 38, wherein said inflammation is
inflammatory bowel disease.

18

83. (New) The method of claim 40, wherein said skin disease is psoriasis.